newsfilter
← Latest News
GlobeNewswire·

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

VYGR
  • Voyager Therapeutics presented six-month GLP toxicology data for investigational gene therapy VY1706 at AAIC 2026 in London.
  • VY1706 is a single-dose intravenous gene therapy targeting intracellular & extracellular tau for Alzheimer's disease.
  • Data showed VY1706 was well-tolerated with no adverse findings in the CNS, dorsal root ganglia, or peripheral organs up to the highest dose tested.
  • A single IV dose achieved sustained tau protein reduction of up to 75% in key brain regions of non-human primates over six months.
  • The therapy utilizes the ALPL receptor to cross the blood-brain barrier, supporting cross-species translatability.
  • The FDA granted Investigational New Drug (IND) clearance for VY1706 in June 2026.
  • A clinical trial in adults with early Alzheimer's disease is expected to begin dosing in the second half of 2026.
  • Previous three-month GLP data for VY1706 was presented at the ASGCT 2026 Annual Meeting in May.